Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis

Abstract

Summary Secondary progressive multiple sclerosis (SP-MS) is the second most common form of MS globally. An effective drug for patients with SP-RS has long been missing from the market.

Siponimod, a selective sphingosine-1-phosphate receptor modulator, is indicated in adult SP-RS patients with evidence of disease activity and is the first agent shown to slow clinically confirmed progression.

Keywords

• multiple sclerosis
• secondary progression
• siponimod
• safety
• effectivity
• long-term data